Bismuthene nanodiscs use mild heat to switch on gene editing that dismantles a tumor’s heat defenses, creating a feedback loop that kills cancer cells more effectively.
(Nanowerk Spotlight) Tumor cells can withstand surprising amounts of heat. When their temperature rises into the 42 to 46 °C range, they rapidly produce heat shock proteins, molecular chaperones that stabilize damaged cellular structures and keep the cell alive. This built-in defense is the central obstacle facing photothermal cancer therapy, which uses nanoparticles to convert laser light into localized heat inside tumors.
Temperatures high enough to overwhelm the heat shock response risk damaging surrounding healthy tissue. Temperatures safe enough for patients let the tumor ride it out.
Drugs that block heat shock proteins directly have shown some effect, but they depend on variable chemical conditions inside each tumor and can cause side effects elsewhere in the body. A cleaner solution would be to disable the genetic instructions for heat resistance before applying thermal treatment, permanently removing the tumor’s ability to protect itself.
Two advances now make this approach practical: CRISPR/Cas9 gene editing, which can cut and silence specific genes with high precision, and bismuthene, a two-dimensional form of the element bismuth that converts near-infrared light into heat efficiently and degrades into ions the body can excrete, avoiding the long-term accumulation problems of gold or carbon alternatives.
The system targets triple-negative breast cancer, a subtype behind roughly 20% of breast cancer diagnoses. These tumors lack the three cellular receptors that most targeted therapies depend on, leaving patients with few options beyond chemotherapy and radiation.
Rather than simply using heat to destroy tumor cells, the platform treats mild heating as a programmable switch that activates gene editing inside the tumor, and that editing in turn strips away the cell’s heat defenses.
Schematic of the bismuthene-based thermogenetic CRISPR-photothermal platform for overcoming tumor thermotolerance in triple-negative breast cancer. (Image: Reproduced with permission from American Chemical Society) (click on image to enlarge)
At the core of the platform are hexagonal bismuthene nanodiscs roughly 50 nm across. These discs absorb 660 nm near-infrared light and convert it to heat, reaching approximately 48 °C at a concentration of 200 ppm after 5 minutes of laser exposure. Onto their positively charged surface, the researchers loaded CRISPR/Cas9 plasmids carrying a guide RNA designed to cut the gene for cyclin-dependent kinase 7, or CDK7. This enzyme drives cell division and gene transcription, and its overexpression correlates with poor outcomes in triple-negative breast cancer. Disrupting CDK7 also triggers DNA damage that suppresses production of HSP70, the principal heat shock protein behind thermotolerance.
To protect the cargo and direct it to tumor cells, the team wrapped the loaded discs in a manganese-based porous coating and topped the assembly with hyaluronic acid, a sugar polymer that latches onto CD44 receptors abundant on triple-negative breast cancer cells. The manganese layer doubles as an MRI contrast agent by releasing manganese ions. The overall structure swells in the mildly acidic environment of tumors and cellular compartments, loosening the coating and releasing the gene-editing payload. Plasmid loading efficiency exceeded 95%, and the particles remained stable in serum for 30 days.
In cell culture experiments with MDA-MB-231 triple-negative breast cancer cells, the nanoparticles escaped the cell’s digestive compartments within 8 hours and delivered functional CRISPR/Cas9 at rates matching a commercial reagent. The system silenced roughly 57% of CDK7 expression, and DNA sequencing confirmed targeted mutations at the intended site.
Adding 660 nm laser irradiation at 0.5 W/cm² for 5 minutes raised the local temperature to about 45 °C, which enhanced plasmid release and editing activity. HSP70 levels dropped sharply while the related protein HSP90 remained unchanged, confirming selective disruption of the heat resistance pathway.
The combined treatment produced the highest rates of programmed cell death and also triggered immunogenic cell death, a process in which dying tumor cells release alarm signals that recruit and activate immune cells.
Mouse experiments using implanted MDA-MB-231 tumors tested whether these laboratory results would translate to a living system. Animals received intratumoral injections every 3 days for four doses, followed by localized laser treatment 6 hours after each injection.
Over 21 days, the combination of gene editing and photothermal therapy shrank tumor volume by more than 93% and tumor mass by 86% compared with untreated controls. Blood markers for liver and kidney function remained normal, and microscopic examination of major organs revealed no tissue damage across any treatment group.
Analysis of treated tumors revealed how the two therapies reinforce each other. Mild heating improved cellular uptake of the nanoparticles, which boosted gene-editing efficiency well beyond what the particles achieved without laser activation. The resulting CRISPR-induced mutations then silenced CDK7 and collapsed HSP70 production, stripping away the tumor’s heat shield.
With that defense gone, tumor cells crossed the threshold for heat-induced death faster and at lower peak temperatures than tumors receiving photothermal therapy alone. And because CRISPR creates permanent changes in DNA, the suppression of CDK7 and HSP70 persisted after treatment stopped, explaining the durable tumor control observed throughout the study.
The practical implication is that effective tumor destruction no longer requires aggressive heating. By using mild warmth as a trigger for gene editing rather than as the primary killing mechanism, the platform opens a path toward lower thermal doses with less harm to surrounding tissue.
Room-temperature assembly and a single-injection treatment protocol further simplify manufacturing and administration compared with gold nanoparticle systems requiring elaborate surface chemistry or multi-drug regimens that pair heat with separate inhibitor compounds. Because CDK7 and heat shock proteins play roles across many solid tumor types, this strategy of using nanomaterials as programmable heat switches for gene editing could extend well beyond breast cancer.
For authors and communications departmentsclick to open
Lay summary
Prefilled posts
Nanowerk Newsletter
Get our Nanotechnology Spotlight updates to your inbox!
Thank you!
You have successfully joined our subscriber list.
Become a Spotlight guest author! Join our large and growing group of guest contributors. Have you just published a scientific paper or have other exciting developments to share with the nanotechnology community? Here is how to publish on nanowerk.com.
